{
    "nctId": "NCT01088750",
    "title": "First International Inter-Group Study for Nodular Lymphocyte-Predominant Hodgkin's Lymphoma in Children and Adolescents",
    "symPyJSON": {
        "type": "and",
        "operands": [
            {
                "type": "and",
                "operands": [
                    {
                        "type": "variable",
                        "value": "nodular lymphocyte-predominant Hodgkin's lymphoma confirmed by reference pathology"
                    },
                    {
                        "type": "variable",
                        "value": "initial stage IA/IIA (according to local staging) or relapse stage IA or IIA and residual tumour after relapse biopsy and no additional surgery planned in nLP patients relapsing after surgery alone"
                    },
                    {
                        "type": "variable",
                        "value": "patient aged under 18 years at time of diagnosis"
                    },
                    {
                        "type": "variable",
                        "value": "written informed consent of the patient and/or the patient's parents or guardian according to national laws"
                    },
                    {
                        "type": "variable",
                        "value": "Must have maximum age of 17 Years"
                    }
                ]
            },
            {
                "type": "not",
                "operands": [
                    {
                        "type": "or",
                        "operands": [
                            {
                                "type": "variable",
                                "value": "pre-treatment of Hodgkin's lymphoma differing from study protocol"
                            },
                            {
                                "type": "variable",
                                "value": "Any extra-nodal involvement"
                            },
                            {
                                "type": "variable",
                                "value": "Inability to fulfil protocol requirements for imaging (CT, MRI, FDG-PET) at staging and response assessment"
                            },
                            {
                                "type": "variable",
                                "value": "known hypersensitivity or contraindication to study drugs"
                            },
                            {
                                "type": "variable",
                                "value": "prior chemotherapy or radiotherapy"
                            },
                            {
                                "type": "variable",
                                "value": "Current or recent therapy (within 30 days prior to the start of trial treatment) with steroids"
                            },
                            {
                                "type": "variable",
                                "value": "Current or recent (within 30 days prior to the start of trial treatment) treatment with another investigational drug or participation in another investigational trial"
                            },
                            {
                                "type": "variable",
                                "value": "other (simultaneous) malignancies"
                            },
                            {
                                "type": "variable",
                                "value": "severe concomitant diseases (e.g. immune deficiency syndrome)"
                            },
                            {
                                "type": "variable",
                                "value": "known HIV positivity"
                            },
                            {
                                "type": "variable",
                                "value": "pregnancy and / or lactation"
                            },
                            {
                                "type": "variable",
                                "value": "females who are sexually active refusing to use effective contraception (oral contraception, intrauterine devices, barrier method of contraception in conjunction with spermicidal jelly or surgical sterile) (except for surgery only)"
                            }
                        ]
                    }
                ]
            }
        ]
    },
    "symPyExpression": "And(Symbol('Must have maximum age of 17 Years'), Symbol('initial stage IA/IIA (according to local staging) or relapse stage IA or IIA and residual tumour after relapse biopsy and no additional surgery planned in nLP patients relapsing after surgery alone'), Symbol(\"nodular lymphocyte-predominant Hodgkin's lymphoma confirmed by reference pathology\"), Symbol('patient aged under 18 years at time of diagnosis'), Symbol(\"written informed consent of the patient and/or the patient's parents or guardian according to national laws\"), Not(Or(Symbol('Any extra-nodal involvement'), Symbol('Current or recent (within 30 days prior to the start of trial treatment) treatment with another investigational drug or participation in another investigational trial'), Symbol('Current or recent therapy (within 30 days prior to the start of trial treatment) with steroids'), Symbol('Inability to fulfil protocol requirements for imaging (CT, MRI, FDG-PET) at staging and response assessment'), Symbol('females who are sexually active refusing to use effective contraception (oral contraception, intrauterine devices, barrier method of contraception in conjunction with spermicidal jelly or surgical sterile) (except for surgery only)'), Symbol('known HIV positivity'), Symbol('known hypersensitivity or contraindication to study drugs'), Symbol('other (simultaneous) malignancies'), Symbol(\"pre-treatment of Hodgkin's lymphoma differing from study protocol\"), Symbol('pregnancy and / or lactation'), Symbol('prior chemotherapy or radiotherapy'), Symbol('severe concomitant diseases (e.g. immune deficiency syndrome)'))))"
}